DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20192501

Effect of brimonidine on central corneal thickness in normal tension glaucoma patients

Neethu K. V., Latha N. V., Praveena K. K.

Abstract


Background: Brimonidine is a potent ocular hypotensive agent widely used in glaucoma treatment. A reduction in central corneal thickness can lead to an underestimation of intraocular pressure by Goldmann applanation tonometry and vice versa. The aim of this study is to determine whether brimonidine has an effect on central corneal thickness.

Methods: 30 eyes of patients who attended the Ophthalmology OPD between the time period October 2017 and June 2018 who were newly diagnosed with normal tension glaucoma with no history of any systemic illness or not on any medication were included. Each patient underwent a complete ophthalmic evaluation including fundus examination, visual field assessment, intraocular pressure, central corneal thickness measurement by pachymetry before as well as 1 month and 6 months after starting treatment with 0.2% topical brimonidine twice daily.

Results: Administration of brimonidine 0.2% resulted in an increase in central corneal thickness from 525±21 µm before starting brimonidine to 528±21 µm (p<0.05) after 1 month and 535±20 µm (p<0.001) after 6 months. It also resulted in a reduction in intraocular pressure from an initial value of 16±2 mmHg before starting brimonidine to 14±2 mmHg (p<0.05) and 13±2 mmHg (p<0.05), 1month and 6 months after starting treatment, respectively.

Conclusions: The data presented in this study show that topical administration of 0.2% brimonidine twice daily results in a significant increase in central corneal thickness in patients with normal tension glaucoma.


Keywords


Brimonidine, Central corneal thickness, Normal tension glaucoma

Full Text:

PDF

References


Kim M, Kim TW, Park KH, Kim JM. Risk factors for primary open-angle glaucoma in South Korea: the Namil study. Jpn J Ophthalmol. 2012;56(4):324-9.

Ehlers N, Hansen FK. Central corneal thickness in low-tension glaucoma. Acta Ophthalmol. 1974;52(5):740-6.

Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000;1(4):815-34.

Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response and dosing studies. Surv Ophthalmol. 1996;41:S19-26.

Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Opthalmol. 1995;113(12):1514-7.

Acheampong AA, Shackleton M, John B, Burke J, Wheeler L, Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab Dispos. 2002;30(4):421-9.

Grueb M, Bartz-Schmidt KU, Rohrbach JM. Adrenergic regulation of cAMP/protein kinase A pathway in corneal epithelium and endothelium. Ophthal Res. 2008;40(6):322-8.

Grueb M, Wallenfels-Thilo B, Denk O. Monoamine receptors in human corneal epithelium and endothelium. Acta Ophthalmol Scand. 2006;84(1):110-5.

Grueb M, Mielke J, Rohrbach JM, Schlote T. Effect of brimonidine on central corneal thickness. J Ocul Pharmacol Ther. 2011;27(5):503-9.

Fan S, Camras CB, Toris CB. Effects of Central Corneal Thickness on the Efficacy of Brimonidine and Latanoprost. Investigative Ophthalmol Visual Science. 2004 May 1;45(13):946.

Gandolfi SA, Cimino L, Mora P. Effect of brimonidine on intraocular pressure in normal tension glaucoma: a short term clinical trial. Eur J Ophthalmol. 2003 Aug-Sep;13(7):611-5.